Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P. Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. New England Journal Of Medicine 2013, 369: 1892-1903. PMID: 24206457, DOI: 10.1056/nejmoa1303154.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseGlomerular filtration rateAngiotensin receptor blockersAcute kidney injuryCombination therapyEnd pointKidney injuryDiabetic nephropathyPrimary end-point eventAngiotensin-converting enzyme inhibitorPrimary end pointSecondary end pointsCombination therapy groupRenal end pointsRisk of hyperkalemiaEnd-point eventsType 2 diabetesBody surface areaConclusion Combination therapyAngiotensin inhibitionCardiovascular eventsMonotherapy groupAdverse eventsCreatinine ratioRenal disease